# 510(k) SUMMARY

Submitter's Name/Address Submitter's Name: Submitter's Address:

Phone:   
Fax:   
Establishment Registration Number:   
Owner/Operator Number: Tokyo Boeki Medisys Inc.   
1-14-21 Higashi-Toyoda, Hino Tokyo 197-0823   
+81-42-532-2771   
+81-42-532-2772   
3004378324   
9060135

# Contact Person (United States Agent)

Name of Agent: Agent's Business Name: Street Address:

Phone:   
Fax:   
E-mail address:   
James M. Clinton   
Quality and Regulatory Consulting, LLC   
5105 Fairoaks Road   
Durham, NC 27712-2078   
919-247-0479   
919-287-2551   
clintonjm@earthlink.net

Date of Preparation of this Summary:

January 6, 2012

Device Trade or Proprietary Name:

Biolis 12i

Device Common Name:

Clinical Chemistry Analyzer (with optional ISE Module)

Classification Numbers/Class:

75JJE, Class I   
75JGS, Class II   
75CEM, Class II   
75CGZ, Class II   
75CFR Class II

# 510(k) Summary:

This summary of 510(k) safety and effectiveness information is being submited in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(K) number is : K110520

# Description:

Using photometry, the Biolis 12i instrument measures the glucose concentration in serum by monitoring the change in absorbance at 340 nm. Additionally, the Biolis 12i with lon-Selective Elective module additionallymeasures the concentration of the electrolytes, sodium, potassium and chloride i serum, using indirect potentiometry.

# Intended Use:

The Biolis 12i is a discrete chemistry analyzer with ion-selective electrode (SE), with direct quantitative measurement of sodium, potassium, chloride, and glucose in serum. It is a device intended for the in-vitro, spectrophotometric determination of general chemistry assays for clinicaluse. The Biolis 12i includes an optional lon Selective Electrode (ISE) module for the measurement of soum, potassium and chloride in serum. The Biolis i is not or Point-Of-are testig.It is foro diagnostic use only.

Sodium measurements are used in the diagnosis and treatment diseases involving electrolyte imbalance.

Potassium measurements monitor electrolyte balance and in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.

Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders.

The Biolis 12i analyzer with glucose hexokinase assay is intended to measure glucose quantitatively in human serum.Glucose measurements are use in the diagnosis and treatment of carbohyat metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic glycemia, and of the pancreatic isle cell carcinoma I

# Substantial Equivalence:

Substantial equivalence has been demonstrated between Sirrus (K0421169) running Glucose reagents (K971467) and the Biolis 12i for measuring glucose in serum. These analyzers are calibrated with known concentration calibrator material and both measure specific concentrations using photometry and electrolytes using identical ion selective electrode modules In addition, substantial equivalence has been demonstrated between the Prestige 24i (K040958) ar the Biolis 12i with an optional lon Selective Electrode Module for measuring sodium, potassium and chlorie in seu. These two analyzers are usd to analyze or elecolysThese analyze calirated with known concentration calibrator material and both utilize lon-Selective Electrodes.

Comparison table with Sirrus (Glucose)   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New DeviceBiolis 12i</td><td rowspan=1 colspan=1>PredicateSirrus(K042169)</td></tr><tr><td rowspan=1 colspan=1>General</td><td rowspan=1 colspan=1>cYanmaGentaYellowb</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>System Principle</td><td rowspan=1 colspan=1>Discrete, single line randomaccess, multi-test analysis</td><td rowspan=1 colspan=1>Discrete, random access,multi-test analysis</td></tr><tr><td rowspan=1 colspan=1>Throughput</td><td rowspan=1 colspan=1>90 tests</td><td rowspan=1 colspan=1>240 tests</td></tr><tr><td rowspan=1 colspan=1>Configuration</td><td rowspan=1 colspan=1>Analytical unit, Control unit</td><td rowspan=1 colspan=1>Analytical unit, Control unit</td></tr><tr><td rowspan=1 colspan=1>Measurement modes</td><td rowspan=1 colspan=1>Absorbance</td><td rowspan=1 colspan=1>Absorbance</td></tr><tr><td rowspan=1 colspan=1>Detector</td><td rowspan=1 colspan=1>Photo-diode</td><td rowspan=1 colspan=1>Photo-diode</td></tr><tr><td rowspan=1 colspan=1>Optical system</td><td rowspan=1 colspan=1>Wavelength range of 340 to800nm</td><td rowspan=1 colspan=1>Wavelength range of 340 to800nm</td></tr><tr><td rowspan=1 colspan=1>Light source</td><td rowspan=1 colspan=1>Tungsten halogen lamp</td><td rowspan=1 colspan=1>Tungsten halogen lamp</td></tr><tr><td rowspan=1 colspan=1>Reaction cuvettes</td><td rowspan=1 colspan=1>Plastics, semi disposal</td><td rowspan=1 colspan=1>Plastics, semi disposal</td></tr><tr><td rowspan=1 colspan=1>Path length</td><td rowspan=1 colspan=1>8mm</td><td rowspan=1 colspan=1>8mm</td></tr><tr><td rowspan=1 colspan=1>Reaction time</td><td rowspan=1 colspan=1>Maximum 10min.</td><td rowspan=1 colspan=1>Maximum 10min.</td></tr><tr><td rowspan=1 colspan=1>Incubation temperature</td><td rowspan=1 colspan=1>37C +/- 0.1</td><td rowspan=1 colspan=1>37C +/-0.1°C</td></tr><tr><td></td><td></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Quantitative determination ofglucose in serum</td><td rowspan=1 colspan=1>Quantitative determination ofglucose in serum</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric endpoint usingglucose hexokinase.</td><td rowspan=1 colspan=1>Photometric endpoint usingglucose</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum,</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>2 uL</td><td rowspan=1 colspan=1>3 uL</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>340 /405 nm</td><td rowspan=1 colspan=1>340 /405 nm</td></tr><tr><td rowspan=1 colspan=1>Reaction type</td><td rowspan=1 colspan=1>Endpoint</td><td rowspan=1 colspan=1>Endpoint</td></tr><tr><td rowspan=1 colspan=1>Read Point</td><td rowspan=1 colspan=1>Read period:19 - 20 cycles(30 seconds per cycle)</td><td rowspan=1 colspan=1>Read period: 50 - 52 cycles(15 seconds per cycle)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# Comparison Table with Prestige 24i (ISE)

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New DeviceBiolis 12i</td><td rowspan=1 colspan=1>PredicatePrestige 24i (K040958)</td></tr><tr><td rowspan=1 colspan=1>General</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>System Principle</td><td rowspan=1 colspan=1>Discrete, single line randomaccess, multi-test analysis</td><td rowspan=1 colspan=1>Discrete, random access,multi-test analysis</td></tr><tr><td rowspan=1 colspan=1>Throughput</td><td rowspan=1 colspan=1>100 tests including ISE tests</td><td rowspan=1 colspan=1>400 tests including ISE tests</td></tr><tr><td rowspan=1 colspan=1>Configuration</td><td rowspan=1 colspan=1>Analytical unit, Control unit</td><td rowspan=1 colspan=1>Analytical unit, Control unit</td></tr><tr><td rowspan=1 colspan=1>Measurement modes</td><td rowspan=1 colspan=1>Absorbance</td><td rowspan=1 colspan=1>Absorbance</td></tr><tr><td rowspan=1 colspan=1>Detector</td><td rowspan=1 colspan=1>Photo-diode</td><td rowspan=1 colspan=1>Photo-diode</td></tr><tr><td rowspan=1 colspan=1>Optical system</td><td rowspan=1 colspan=1>Wavelength range of 340 to</td><td rowspan=1 colspan=1>Wavelength range of 340 to</td></tr></table>

# Tokyo Boeki Medisys System Ltd.

1-14-21 Higashi-Toyoda, Hino, Tokyo 191-0052, Japan Phone: +81-42-587-2965 Fax: $+ + 8 1 - 4 2 - 5 8 7 - 7 7 8 1$

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>800nm</td><td rowspan=1 colspan=1>800nm</td></tr><tr><td rowspan=1 colspan=1>Light source</td><td rowspan=1 colspan=1>Tungsten halogen lamp</td><td rowspan=1 colspan=1>Tungsten halogen lamp</td></tr><tr><td rowspan=1 colspan=1>Reaction cuvettes</td><td rowspan=1 colspan=1>Plastics, semi disposal</td><td rowspan=1 colspan=1>Plastics, semi disposal</td></tr><tr><td rowspan=1 colspan=1>Path length</td><td rowspan=1 colspan=1>8mm</td><td rowspan=1 colspan=1>8mm</td></tr><tr><td rowspan=1 colspan=1>Reaction time</td><td rowspan=1 colspan=1>Maximum 10min.</td><td rowspan=1 colspan=1>Maximum 10min.</td></tr><tr><td rowspan=1 colspan=1>Incubation temperature</td><td rowspan=1 colspan=1>37°C +/- 0.1C</td><td rowspan=1 colspan=1>37°C +/- 0.1C</td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>ISE</td><td rowspan=1 colspan=1>The ISE module is operated onthe Biolis 12i integrated system.</td><td rowspan=1 colspan=1>The ISE module is operated onthe Biolis 24i integrated system</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Quantitative determination ofNa, K and Cl</td><td rowspan=1 colspan=1>Quantitative determination ofNa, K and Cl</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Ion selective electrode</td><td rowspan=1 colspan=1>lon selective electrode</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum,</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>60 uL</td><td rowspan=1 colspan=1>60 uL</td></tr><tr><td rowspan=1 colspan=1>Analysis time</td><td rowspan=1 colspan=1>100 seconds</td><td rowspan=1 colspan=1>100 seconds</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# The validated system is described below.

<table><tr><td rowspan=1 colspan=1>Analyzer:</td><td rowspan=1 colspan=1>Tokyo Boeki BiOLiS 12i Analyzer with lon -selective electrode module usingdirect potentiometry.Serial numbers are listed on individual study reports</td></tr><tr><td rowspan=1 colspan=1>Software</td><td rowspan=1 colspan=1>Interface software version: 1.70ISE ROM software version: 3.05</td></tr><tr><td rowspan=1 colspan=1>Reagent:</td><td rowspan=1 colspan=1>Carolina Liquid Chemistries Glucose Reagent, Kit product no. BL-208 (alsopackaged as AU-208). Lot numbers are listed on individual study reports</td></tr><tr><td rowspan=2 colspan=1>Calibratorfor glucose</td><td rowspan=1 colspan=1>Pointe Scientific Chemistry Calibratorproduct no. C7506-50, lot 11802, exp. March 2014Premarket clearance reference no.: K070207</td></tr><tr><td rowspan=1 colspan=1>The 185 mg/dL glucose set point for the Pointe Calibrator was verified for theCarolina Liquid Chemistries Glucose Reagent by comparing the calibrator toNIST SRM 965b, Glucose in Frozen Serum.  The Pointe Calibrator wasassayed eight times over each of four analytical runs against NIST standardlevels 3 and 4 which were each assayed in duplicate. The glucoseconcentration of the Pointe Calibrator was calculated for each run by linearinterpolation the NIST assay values and their respective certified values of 118.5mg/dL and 294.5 mg/dL. The mean glucose result of the Pointe Calibrator overthe four runs was 185.6 mg/dL.</td></tr><tr><td rowspan=1 colspan=1>Calibratorfor ISE</td><td rowspan=1 colspan=1>Calibrator 1 and Calibrator 2Manufacturer: Tokyo Boeki MedisysLot numbers are listed on individual study reportsPremarket clearance reference no: K040958</td></tr></table>

# Performance Characteristics:

ISE

Acorrelation analysis between the Prestige i and the Biolisi yielded the following rults:

<table><tr><td rowspan=1 colspan=2>RepresentativeMethod</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>Slope(Least-Squares)</td><td rowspan=1 colspan=1>Y-axis intercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Sodium</td><td rowspan=1 colspan=1>0.9872</td><td rowspan=1 colspan=1>1.0204</td><td rowspan=1 colspan=1>-3.1903</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Potassium</td><td rowspan=1 colspan=1>0.9992</td><td rowspan=1 colspan=1>1.0255</td><td rowspan=1 colspan=1>-0.1457</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Chloride</td><td rowspan=1 colspan=1>0.9922</td><td rowspan=1 colspan=1>0.9736</td><td rowspan=1 colspan=1>1.8580</td></tr></table>

# The linearity test yielded the following results:

<table><tr><td rowspan=1 colspan=2>Linearity</td></tr><tr><td rowspan=1 colspan=1>Sodium</td><td rowspan=1 colspan=1>100 - 200 mmol/L (Serum)</td></tr><tr><td rowspan=1 colspan=1>Potassium</td><td rowspan=1 colspan=1>1 - 10 mmol/L (Serum)</td></tr><tr><td rowspan=1 colspan=1>Chloride</td><td rowspan=1 colspan=1>70 - 200 mmol/L (Serum)</td></tr></table>

The precision test results:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Sample 1%CV</td><td rowspan=1 colspan=1>Sample 2%CV</td><td rowspan=1 colspan=1>Sample 3%CV</td></tr><tr><td rowspan=3 colspan=1>4</td><td rowspan=3 colspan=1>Within RunN=20</td><td rowspan=1 colspan=1>Sodium</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>0.93</td></tr><tr><td rowspan=1 colspan=1>Potassium</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>0.94</td></tr><tr><td rowspan=1 colspan=1>Chloride</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.83.</td><td rowspan=1 colspan=1>0.69</td></tr><tr><td rowspan=3 colspan=1>5</td><td rowspan=3 colspan=1>Day byDay-RunN=15</td><td rowspan=1 colspan=1>Sodium</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Potassium</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Chloride</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.4</td></tr></table>

# Interferences

The Interference test yielded the following results:

No

<table><tr><td colspan="1" rowspan="1">Substance</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">Abnormal</td></tr><tr><td colspan="1" rowspan="1">Bilirubin F</td><td colspan="1" rowspan="1">19.7 mg/dL</td><td colspan="1" rowspan="1">19.7 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Bilirubin C</td><td colspan="1" rowspan="1">21 mg/dL</td><td colspan="1" rowspan="1">21 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">488 mg/dL</td><td colspan="1" rowspan="1">488 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Lipemia</td><td colspan="1" rowspan="1">1000mg/dL</td><td colspan="1" rowspan="1">500 mg/dL</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">Abnormal</td></tr><tr><td colspan="1" rowspan="1">Lithium Chloride</td><td colspan="1" rowspan="1">3.20 mmol/L</td><td colspan="1" rowspan="1">3.20 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Sodium Bromide</td><td colspan="1" rowspan="1">37.60 mmol/L</td><td colspan="1" rowspan="1">37.60 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Sodium Salicylate</td><td colspan="1" rowspan="1">4.34 mmol/L</td><td colspan="1" rowspan="1">4.34 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Sodium Thiocyanate</td><td colspan="1" rowspan="1">6.88 mmol/L</td><td colspan="1" rowspan="1">6.88 mmol/L</td></tr></table>

# Conclusion:

The lon Selective Electrode performance data for Sodium, Potassium and Chloride demonstrates that Biolis 12i is substantially equivalent to the Prestige 24i (K040958).

# Glucose Reagent

# Method Comparison

Acrelatin analysis between the Sirrus and the Biolisi yielded the following results:

<table><tr><td rowspan=1 colspan=1>RepresentativeMethod</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>Slope(Least-Squares)</td><td rowspan=1 colspan=1>Y-axis intercept</td></tr><tr><td rowspan=1 colspan=1>GLU</td><td rowspan=1 colspan=1>0.9975</td><td rowspan=1 colspan=1>1.0447</td><td rowspan=1 colspan=1>-4.845</td></tr></table>

# Precision

The precision test results:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Sample 1CV (%)</td><td rowspan=1 colspan=1>Sample 2CV (%)</td><td rowspan=1 colspan=1>Sample 3CV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Within-runN=20</td><td rowspan=1 colspan=1>GLU</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>1.04•</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Between-runN=20</td><td rowspan=1 colspan=1>GLU</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>0.70F</td></tr></table>

# Linearity

The linearity test yielded the following results:

<table><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>0.9997</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.96</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-2.66</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>25 - 5400 mg/dL</td></tr></table>

# Sensitivity

The minimum detection limit test yielded the following results:

<table><tr><td>Minimum Detectable value</td><td>7.83 mg/dL</td></tr></table>

# Interferences

The Interference test yielded the following results:

No significant interference were observed at the following concentration levels

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>Abnormal</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500mg/dL</td><td rowspan=1 colspan=1>500mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>20 mg/dL</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr></table>

# Stability Summary

The calibration stability test yielded the following results:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>2.1     ,</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.1</td></tr></table>

# Conclusion:

The glucose performance data demonstrates that Biolis 12i is substantially equivalent to Sirrus (K 042169)

Tokyo Boeki Medisys Inc.   
c/o James Clinton   
c/o Quality & Regulatory Consulting, LLC. 5105 Fairoaks Rd.   
Durham, NC 27712

Re: k110520 Trade Name: BIOLIS 12i Regulation Number: 21 CFR $\ S 8 6 2 . 1 6 6 5$ Regulation Name: Sodium test system Regulatory Class: Class II Product Codes: JGS, CEM, CGZ, CFR, JJE Dated: February 29, 2012 Received: March 6, 2012

Dear Mr. Clinton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and. Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

2

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# INDICATIONS FOR USE

510(k) Number (if kriown): K110520

Device Name: Biolis 12i

Indications for Use:

The Biolis 12i is a discrete photometric chemistry analyzer with ion-selective electrode (ISE), with direct quantitative measurement of sodium, potassium;, chloride, and glucose in serum. It is a device intended for the in-vitro, spectrophotometric determination of general chemistry assays for clinical use. The Biolis 12i includes an optional lon Selective Electrode (ISE) module for the measurement of sodium, potassium and chloride in serum. The Biolis 12i is not for Point-Of-Care testing. It is for vitro diagnostic use only.

Sodium measurements are used in the diagnosis and treatment diseases involving electrolyte imbalance.

Potassium measurements monitor electrolyte balance and in the diagnosis and treatment o diseases conditions characterized by low or high blood potassium levels.

Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders.

The Biolis 12i analyzer with glucose hexokinase assay is intended to measure glucose quantitatively in human serum. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic glycemia, and of the pancreatic islet cell carcinoma.

Prescription Use (Part 21 CFR 801 Subpart D)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)